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1 Introduction 
‘Sarcopenia’ is defined as the loss of muscle mass and function that occurs 
during normal ageing 1, 2. More recently the term ‘dynapenia’ has been 
suggested to specifically describe the age-associated loss of muscle strength 
(Clark, 2008). However, this term is rarely used and in this article we solely 
use the term ‘sarcopenia’ to describe the age-related loss of both muscle size 
and function. Sarcopenia is often accompanied by fat infiltration or ‘marbling’ 
of skeletal muscles 2, 3. Complications associated with low muscle mass and 
function include a reduced ability to perform ambulatory tasks 4, old age 
disability 5, falls 6, poor recovery after hip fracture or major disease 7 and 
increased mortality 8.  
 
Efforts to research, diagnose and treat sarcopenia are hampered by the lack 
of universally accepted guidelines and cut off points for diagnosing sarcopenia 
9. Criteria that have been proposed to identify or diagnose sarcopenia are the 
ratio of appendicular skeletal muscle mass relative to height 10 or the knee 
extension strength/torque, handgrip strength or calf muscle area at least two 
standard deviations below the mean of a young reference group 11. Recently, 
an European working group on sarcopenia has recommended a diagnosis 
based on measurements of gait speed, grip strength and muscle mass 12.  
 
Sarcopenia is characterised by many alterations of which several stand out. 
Firstly muscle fibres are lost and type 2 fibres atrophy especially after 60 
years of age 2, 13. Secondly, muscle displays ‘anabolic resistance’ which is a 
decreased protein synthesis response to amino acids 14, insulin 15 and 
resistance exercise 16. Related to this, insulin also reduces proteolysis less in 
old muscle than in young 17. Thirdly, satellite cells, as identified by Pax7, 
neural cell adhesion molecule (NCAM) and M-cadherin positivity, are ≈2-fold 
reduced in ≈70 year old human vastus lateralis muscle when compared to ≈20 
year old controls 18. Old muscle also responds with diminished satellite cell 
proliferation to muscle injury resulting in impaired muscle regeneration 18. 
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Many mechanisms have been proposed to cause the aforementioned 
sarcopenia alterations 2 but the overall aetiology is still incompletely 
understood. A possible, contributing cause is that ageing increases systemic 
myostatin activity. Myostatin inhibits muscle growth 19-21 and an increased 
serum concentration of myostatin in mice has been reported to cause muscle 
atrophy 21. Moreover, prolonged absence of myostatin reduces sarcopenia in 
mice implying that presence of myostatin contributes to sarcopenia in this 
species 22. 
 
Until recently it was impossible to test the hypothesis that serum myostatin 
was increased in humans with sarcopenia because serum myostatin levels 
could not be measured reliably 23. A well validated human myostatin assay 
has now been developed (Lakshman et al., 2009). Using this assay it has 
been reported that serum myostatin was significantly higher by 14% in men 
with an average age of 27±5 years and 77% lean body mass than in older 
men with an average age of 66±5 years and 70% lean body mass 23. The 
receptor binding activity of myostatin, however, depends additionally on the 
concentration of myostatin-interacting proteins that can dimerise with 
myostatin to form a latent, inactive complex that can not bind to its receptor. 
These proteins include GDF-associated serum protein-1 (GASP-1) 24, 
follistatin-related gene (FLRG) 25 or follistatin 26.  
 
Myostatin and myostatin-interacting proteins are not the only serum factors 
that have been shown to be associated with muscle size and function. Higher 
concentrations of tumour necrosis factor α (TNFα) were associated with 5-
year declines in muscle mass and grip strength 27 whereas interleukin-6 (IL-6) 
concentrations predicted sarcopenia in women 28. Serum and muscle-specific 
insulin-like growth factor-1 (IGF-1) splice variants have been proposed to 
contribute to sarcopenia 29. IGF-1 concentrations are lower in elderly subjects 
than in young 30, 31 and in the Framingham heart study higher IGF-1 
concentrations were associated with a smaller loss of fat free mass women 28. 
Serum testosterone is often decreased in elderly men 32 and because 
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testosterone increases muscle protein synthesis 33 the decline of free 
testosterone during ageing is a potential cause of sarcopenia. 
 
The main aim of the study was to test the hypothesis that the concentration of 
serum myostatin is higher and/or that the concentrations of myostatin-
interacting factors such as GASP-1, FLRG and follistatin are lower in older  (> 
65 years) men with mild or severe sarcopenia when compared to young men, 
respectively. Sarcopenia was defined on the basis of reduced knee extensor 
torque when compared with young men 11. Quadriceps cross sectional area 
(CSA) was measured using MRI, isometric knee extensor torque during a 
maximal voluntary contraction (MVC) using an isokinetic dynamometer and 
voluntary activation using the twitch interpolation technique 34. Serum TNFα, 
IL-6, IGF-1 and free testosterone were additionally measured to allow 
comparison with previous studies.  
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2 Methods 
2.1 Subject characteristics 
This study was approved by the North and South Scotland Research Ethics 
committees. All the volunteers gave their written informed consent to take part 
in the study. A total of sixty-six men were recruited in Aberdeen (n=52) and 
Edinburgh (n=14). These included 20 young men (22±2 years, body mass 
index (BMI) 24.0±2.5 kg.m-2) as well as 46 older men with mild sarcopenia 
(n=20, 69±3 years, BMI 25.2±2.0 kg.m-2) and severe sarcopenia (n=26, 76±6 
years, BMI 24.7±2.8 kg.m-2; BMI did not differ significantly between groups, 
p=0.30) 11. Because muscle function measurements are easier and cheaper 
to perform than MRI measurements we decided for practical reasons to select 
sarcopenic subjects based on their maximal knee extension torque rather 
than their mid thigh quadriceps CSA. Mild sarcopenia was defined as having a 
MVC between 1 and 2 SD below the mean for the young men while reduction 
in MVC by 2 SD was used as a cut off point for severe sarcopenia. 
 
2.2 Exclusion criteria 
The following exclusion criteria were applied to exclude individuals with 
conditions that affect muscle mass or the serum factors studied 35: Obesity 
(BMI>30 kg/m2) or being underweight (BMI<18 kg/m2); history of myocardial 
infarction within the previous 2 years; cardiac illness: moderate/ severe aortic 
stenosis, acute pericarditis, acute myocarditis, aneurysm, severe angina, 
clinically significant valvular disease, uncontrolled dysrrhythmia, claudication, 
within the previous 10 years; major systemic disease within the last 2 years 
(cancer, rheumatoid arthritis); diabetes; uncontrolled metabolic disease (e.g. 
thyroid disease); thrombophlebitis or pulmonary embolus within the previous 2 
years; history of cerebrovascular disease; severe airflow obstruction; acute 
febrile illness within the previous 3 months; significant emotional distress, 
psychotic illness or depression within the previous 2 years; lower limb arthritis, 
classified by inability to perform maximal contractions of lower limbs without 
severe pain.  
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2.3 Pre-study instructions and blood sampling  
Volunteers were asked not to exercise the day before and arrived in the lab in 
the morning after an overnight fast to control for exercise and nutrition. A BD 
Vacutainer 21 G multi sample blood collection needle was used to obtain 15 
ml of venous blood. After that volunteers received a light breakfast and took 
part in assessment of muscle strength and size. 
 
2.4 Measurement of isometric muscle strength  
The dominant leg of volunteers was tested. MVC was measured as the 
isometric knee extensor torque at 90°. The measurement was performed 
using a Biodex isokinetic dynamometer (System 2; Biodex Medical Systems, 
Shirley, New York, USA) similarly to our previous study 36. The volunteers sat 
upright and MVC was determined as the best of three isometric knee 
extensions lasting approximately 5 s each; 2 min of rest was allowed between 
the attempts.  
 
2.5 Measurement of voluntary activation 
The twitch interpolation technique was used to estimate voluntary activation of 
knee extensors using similar methods as in our previous study 36. A constant 
current electrical stimulator (DS7A; Digitimer, Hertfortshire, U.K.) was used to 
apply a square-wave pulse of 0.5 ms in duration to the quadriceps muscle via 
two surface electrodes (6 x 12 cm). The intensity of electrical stimulation was 
selected individually by applying single stimuli to the tested muscles. During 
this procedure the current was increased until no increment in single twitch 
torque could be detected by an additional 10% increase in current strength. 
Three 5 s MVCs were performed with a 2 min rest in-between. At ~3 s of a 
MVC effort an electrical pulse was superimposed on the voluntary contraction. 
The same electrical stimulus was repeated 1–2 s after the MVC. These single 
twitches were used to calculate voluntary activation of knee extensors using 
the following formula: Voluntary activation index (%) = 100 - superimposed 
twitch torque/control twitch torque x 100%. 
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2.6 MRI measurement of the quadriceps mid-thigh CSA 
Mid thigh, i.e. the midpoint between trochanterion and tibiale laterale, was 
marked using a cod liver oil capsule which is easy to detect on a MRI scan. 
Sequential MRI images were obtained using a Phillips 3 Tesla scanner. Dual-
mode 80 mT/m gradient and parallel imaging systems were used to achieve 
high resolution images. T1 weighted cross sectional images of right and left 
thigh were obtained at a slice thickness of 3 mm with 12 mm interslice 
distance. The sum of the largest cross sectional areas (CSA) of vastus 
lateralis, vastus medialis, vastus intermedius and rectus femoris for the 
dominant leg was measured by two independent observers and the was used 
for analysis. 
 
2.7 Immunoassays 
The venous blood samples were centrifuged to obtain serum, transported on 
dry ice and stored at -80 °C until further analysis. Enzyme-linked 
immunosorbent assays for the following analytes were performed on serum 
samples from all subjects: total myostatin, follistatin, FLRG, GASP-1, IGF-I, 
TNFα, IL-6 and free testosterone (Table 1). The validation of the total 
myostatin assay has previously been published 23.The assays were validated 
for use in serum using either the manufacturers or published protocols with 
the following three exceptions: 1) For follistatin an extra low calibrator point of 
0.125 ng/ml was added; 2) For FLRG and GASP-1 Immunoglobulin Inhibiting 
Reagent (IIR, Sera Laboratories International, West Sussex, UK) was 
routinely added to the standard and samples; 3) For myostatin the calibrator 
matrix was 5% BSA /PBS rather than the serum-based calibrator used in the 
earlier study 23 as we found that the Belgian blue calf serum had high batch to 
batch variability. 
 
For each of the assays three validation samples corresponding to low, 
medium and high analyte concentrations were used to determine assay 
precision. Intra- and inter assay CVs for each assay was determined in six 
separate aliquots of low, medium and high validation samples in five 
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independent analytical runs (Table 1). Subsequently these samples served as 
quality controls for each analyte on each assay plate. 
 
2.8 Statistical analysis 
All data are given as mean ± standard deviation (SD). We tested the 
hypothesis that variables differed between the young, mildly sarcopenic and 
severely sarcopenic groups by using an one-factorial ANOVA. Homogeneity 
of variance was tested by Levene’s test. If variance did not differ significantly 
then a least significant difference (LSD) test was used post hoc. If variances 
differed significantly then Dunnett’s test was used post hoc as this test does 
not require equal variances. To compare serum variables to muscle size and 
functional variables, Pearson’s product-moment correlation coefficient was 
calculated. All statistical tests were computed using SPSS 17.0.  
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3 Results 
3.1 Muscle function and size 
Data on muscle function and size are shown in figure 1. For the mildly and 
severely sarcopenic groups, quadriceps CSA was reduced by 24% and 33% 
while MVC was depressed by 31% and 52% compared with young men, 
respectively (Figure 1). Voluntary muscle activation did not differ significantly 
difference between groups (p=0.59). It was 94.9±3.9% in the young (n=18), 
95.3±3.8% (n=21) in the mildly sarcopenic and 93.4±7.0% (n=11) in the 
severely sarcopenic. Reduced subject numbers are because not all men 
volunteered to take part in this experiment.  
 
3.2 Myostatin and myostatin interacting factors 
Serum concentrations of myostatin, follistatin, FLRG and GASP-1 did not 
differ between the groups (Figure 2). However, there was a trend for 
decreased FLRG concentrations in the sarcopenic cohorts (p=0.06; Figure 2): 
FLRG was 26% lower in the mildly sarcopenic and 19% lower in the severely 
sarcopenic group than in the young, respectively. None of the myostatin-
related serum factors correlated significantly with either isometric knee 
extension torque or quadriceps CSA in older men. 
 
3.3 Other serum factors 
IL-6 and TNFα did not differ significantly between groups but IGF-1 and free 
testosterone were both significantly lower in the mildly and severely 
sarcopenic groups than in the young (Figure 3). However, IGF-1 did not 
correlate with isometric knee extension torque nor with quadriceps CSA in the 
pooled mildly and severely cohorts. In contrast, free testosterone correlated 
negatively with both isometric knee extension torque (r=-0.40; p=0.01) and 
quadriceps CSA (r=-0.36; p=0.02) in the pooled mildly and severely 
sarcopenic cohorts. 
Page 9 of 21
http://mc.manuscriptcentral.com/jgbs
Manuscripts submitted to Journal of Gerontology: Biological Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 10 
4 Discussion 
This is the first report where both serum myostatin and major myostatin-
interacting proteins have both been measured in relation to human 
sarcopenia.  
 
4.1 Muscle function and size 
MVC was reduced 7% and 19% more than quadriceps CSA in the mildly and 
severely sarcopenic groups when compared with young, respectively (Figure 
1). The observed difference between MVC and CSA was not due to reduced 
voluntary activation. This suggests that specific muscle strength or muscle 
quality, defined as the ratio of muscle force to CSA, is reduced in the 
sarcopenic subjects compared with young 37, 38. 
 
4.2 Myostatin-related serum factors 
Earlier studies on serum myostatin in diseases with muscle atrophy have 
been considered unreliable 39 because of the antibodies and assays used 23. 
To our knowledge, this is only the second publication where myostatin has 
been measured in young and old men using a well validated myostatin assay 
23. However, serum myostatin concentrations were 40%-50% lower in our 
study (Figure 2) than those measured in the first study 23. Also, myostatin was 
reported to be higher by 1 ng.ml-1 in the young than in the old men 23 whereas 
we did not find any difference. The most likely explanation for the on average 
higher concentrations reported by Lakshman et al. (2009) is that these 
investigators used myostatin-null Belgian Blue cattle serum as a calibrator 
matrix for their myostatin assay. In our hand the commercially Belgian blue 
calf serum had a high batch to batch variability which is why we decided to 
use 5% BSA/PBS. This is the most likely explanation for the observed, 
systematic difference in serum myostatin concentrations. A possible reason 
for the significant, 1 ng.ml-1 myostatin difference in Lakshman et al. (2009) is 
that the BMI of the old men was 2.8 kg.m-2 higher in the old men than in the 
young men as higher myostatin. In our study the groups were more closely 
matched with respect to BMI and the largest difference between young and 
old men was 1.2 kg.m-2.  
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To our knowledge this is the first study where the myostatin and the 
myostatin-interacting factors GASP-1 24, FLRG 25 or follistatin 26 have all been 
measured in human serum (Figure 2). Myostatin, GASP-1 and FLRG and 
follistatin did not differ significantly between groups nor did they correlate with 
isometric knee extension torque or m. quadriceps CSA. This suggests that at 
least the serum concentrations of myostatin and myostatin-interacting factors 
are unlikely to be a contributing cause for sarcopenia. This does not exclude 
the possibility that local or serum myostatin and myostatin-interacting factors 
respond differently to exercise, nutrition or hormones between young and old 
men. The FLRG findings should be verified in future studies as they were on 
the borderline of significance (p=0.06) with a trend towards ≈20% lower FLRG 
concentrations in the sarcopenic men. Lower FLRG levels would result in a 
lower concentration of the latent, inactive complex (Hill et al., 2002) and a 
higher concentration of free myostatin.  
 
4.3 Cytokines 
Neither IL-6 nor TNFα differed significantly between groups nor did these 
serum factors correlated with isometric knee extension strength or m. 
quadriceps cross sectional area. Our data contradict previous studies showing 
that TNFα was a predictor of the decline of muscle mass and grip strength 27 
and that IL-6 was a predictor of sarcopenia albeit only in women 28.  
 
4.4 IGF-1 
IGF-1 was significantly lower in older men with mild and severe sarcopenia 
than in the young, confirming previous reports 30, 31. However, IGF-1 did not 
correlate with isometric leg extension torque nor with quadriceps CSA in the 
older men. IGF-1 stimulates protein synthesis via the mTOR system 40 but 
muscle protein synthesis does differ little or not at all between fasted young 
and old males 14 and certainly not by the magnitude by which IGF-1 differs. 
Thus the contribution of lowered serum IGF-1 levels to sarcopenia is unclear.  
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4.5 Free testosterone 
Free testosterone was significantly lower in the sarcopenic groups and was 
the only factor that correlated significantly with isometric leg extension 
strength and m. quadriceps CSA in the elderly and in all subjects. This finding 
is in line with other studies that report decreased free testosterone in elderly 
men 32 and that free testosterone was a predictor of muscle mass explaining 
2.6% of muscle mass variation 41.  
 
4.6 Conclusion 
This is the first study to report the measurement of four myostatin-related 
serum factors in young and older, sarcopenic men. None of the myostatin-
related factors differed in between groups nor correlated with knee extension 
torque or quadriceps CSA in the pooled sarcopenic cohorts. However mean 
FLRG was ≈20% lower in the sarcopenic groups and achieved borderline 
significance (p=0.06). Our findings suggest that therapies that aim at inhibiting 
myostatin in humans 42 do probably not directly target a sarcopenia defect. 
This does not exclude that such therapies may be effective in increasing 
muscle mass and function in sarcopenic individuals.  
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Figure legends 
Figure 1. (a) Maximum voluntary contraction (MVC) measured as isometric 
knee extension torque and (b) quadriceps cross-sectional area for the 
dominant leg (CSA) in young, mildly sarcopenic and severely sarcopenic men 
(mean±SD). For CSA only 24 out of 26 severely sarcopenic subjects could be 
analysed.  
 
Figure 2. (a) Myostatin and myostatin interacting proteins (b-d) in the serum 
of young (n=20), mildly sarcopenic (n=20) and severely sarcopenic (n=26) 
men (mean±SD). For myostatin one outlier in the mildly sarcopenic (42.5 
ng.ml-1) and another in the severely sarcopenic (28.3 ng.ml-1) group has not 
been included in this figure. For myostatin an ANOVA has been performed 
with the outliers included (p value without brackets) and excluded (p value 
inside brackets). Abbreviations: FLRG Follistatin-Related Gene Protein; 
GASP-1 GDF-associated serum protein-1. 
 
Figure 3. Muscle growth related serum variables in the serum of young 
(n=20), mildly sarcopenic (n=20) and severely sarcopenic (n=26) men 
(mean±SD). For TNFα an ANOVA has been performed with the outliers 
included (p value without brackets) and excluded (p value inside brackets). 
Abbreviations: IL-6 Interleukin-6; TNFα Tumour necrosis factor α.
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Figure 1.  (a) Knee extension torque and (b) quadriceps cross-sectional area for the dominant leg 
(CSA) in young, mildly sarcopenic and severely sarcopenic men (mean±SD). For CSA only 24 out of 
26 severely sarcopenic subjects could be analysed.  
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Figure 2. (a) Myostatin and myostatin interacting proteins (b-d) in the serum of young (n=20), 
mildly sarcopenic (n=20) and severely sarcopenic (n=26) men (mean±SD). For myostatin one 
outlier in the mildly sarcopenic (42.5 ng.ml-1) and another in the severely sarcopenic (28.3 ng.ml-1) 
group has not been included in this figure. For myostatin an ANOVA has been performed with the 
outliers included (p value without brackets) and excluded (p value inside brackets). Abbreviations: 
FLRG Follistatin-Related Gene Protein; GASP-1 GDF-associated serum protein-1.  
177x169mm (300 x 300 DPI)  
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Figure 3. Muscle growth related serum variables in the serum of young (n=20), mildly sarcopenic 
(n=20) and severely sarcopenic (n=26) men (mean±SD). For TNFα an ANOVA has been performed 
with the outliers included (p value without brackets) and excluded (p value inside brackets). 
Abbreviations: IL-6 Interleukin-6; TNFα Tumour necrosis factor α.  
177x174mm (300 x 300 DPI)  
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Table 1. Experimental detail for the Elisa assays.  
Elisa assay Supplier Catalogue 
number 
Serum 
dilution 
Intra 
assay 
precision 
(%CV) 
Inter assay 
precision 
(%CV) 
Lower limit 
of quanti- 
fication 
Total 
Myostatin^ 
n/a n/a Neat* 2.5 - 8.5 4.6 -8.3 1172  
pg.ml-1 
Follistatin R&D DFN00 Neat 1.9–3.3 1.5–9.6 0.125  
ng.ml-1 
FLRG R&D DY1288 01:09 2.1–4.5 10.1–14.8 2.8  
ng.ml-1 
GASP-1 R&D DY2070 01:15 2.4 - 4.4 2.9 -15.1 468.8  
pg.ml-1 
IL-6 R&D HS600B Neat 6.7 - 8.1 14.1 -19.4 0.16  
ng.ml-1 
TNFα R&D HSTA00D Neat 3.0–13.0 4.9-8.0 1.0  
pg.ml-1 
IGF-I R&D DG100 Neat# 3.3–4.0 2.7–3.9 9.4  
ng.ml-1 
Free Tes-
tosterone 
DRG 
Europe 
EIA-2924 Neat 6.8 - 15.3 10.7 -12.5 0.2  
pg.ml-1 
^In house (Pfizer) antibodies were used to detect myostatin. These were a 
capture (RK35) and detector (RK22) antibody. 
*Neat samples underwent pretreatment prior to assay, resulting in a 1:13.3 
dilution for the assay 
#Neat samples underwent two pretreatment steps, resulting in a 1:100 dilution 
for the assay. 
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